Doxorubicin transport by RALBP1 and ABCG2 in lung and breast cancer.

Doxorubicin transport by RALBP1 and ABCG2 in lung and breast cancer. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Doxorubicin transport by RALBP1 and ABCG2 in lung and breast cancer. Abstract Text:

Sharad S Singhal,Jyotsana Singhal,Maya P Nair,A G Lacko,Yogesh C Awasthi,Sanjay Awasthi,

RALBP1 (RLIP76) is the major transporter of doxorubicin (DOX) in lung cancer cells, and that the difference in sensitivity of small cell lung cancer (SCLC) cells to DOX is due to differential phosphorylation by PKCalpha. Our recent studies have suggested that RALBP1 present in MCF-7 breast cancer cells has significantly lower specific activity for transport of DOX than wild-type recombinant protein, and its level of expression is significantly lower than that in lung cancer cells. In the present study, we have explored whether or not this is a generalized phenomenon for breast cancer, and have compared the relative contributions of RALBP1 and the ABC-family transporter, ABCG2 to total DOX transport activities in two SCLC (H1417 and H1618), two non-small cell lung cancer (NSCLC) (H358 and H520), and three breast cancer (T-47D, MDA-MB231, and MCF-7) cell lines. Results of these studies show lower protein expression and specific activity of RALBP1 in all three breast cancer cell lines as compared with lung cancer cell lines. Furthermore, we demonstrate that RALBP1 contributes only a minor fraction of DOX transport activity in breast cancer cell lines, suggesting that greater DOX sensitivity of breast cancer may be related to lower RALBP1 transporter activity and that the transport mechanisms involved in multidrug resistance of lung and breast cancer are distinct.

Doxorubicin transport by RALBP1 and ABCG2 in lung and breast cancer. Publishing Authors By Initials

SS Singhal,J Singhal,MP Nair,AG Lacko,YC Awasthi,S Awasthi,

For similar proteins: recombinant proteins research abstracts see: proteins: recombinant proteins research

PUBMED ID PMID:

MEDLINE DATE:

Doxorubicin transport by RALBP1 and ABCG2 in lung and breast cancer. Journal Published:

PUBLICATION TYPE: Research Support, Non-U.S. Gov

Journal: International journal of oncology

VOLUME: 30

Page Numbers: 717-25

Journal Abbreviation: Int. J. Oncol.

ISSN: 1019-6439

DAY: 3

MONTH: Mar

YEAR: 2007

Doxorubicin transport by RALBP1 and ABCG2 in lung and breast cancer. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 9306042

Doxorubicin transport by RALBP1 and ABCG2 in lung and breast cancer. Keywords Mesh Terms:

KEYWORDS: Recombinant Proteins

MESH TERMS: chemistry

Chemical & Substance for Abstract: Doxorubicin transport by RALBP1 and ABCG2 in lung and breast cancer. Information

Substance Name: Doxorubicin

Registry Number: 23214-92-8

Grant and Affiliation Information for Doxorubicin transport by RALBP1 and ABCG2 in lung and breast cancer.

AFFILIATION: Department of Chemistry and Biochemistry, University of Texas at Arlington, 700 Planetarium Place, Arlington, TX 76019, USA.

Country: Greece

AGENCY: United States NEI

GRANT: EY 04396

ACRONYM: EY

MEDLINETA: Int J Oncol

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Doxorubicin transport by RALBP1 and ABCG2 in lung and breast cancer Related Publications

• A composite management intervention plus financial incentives reduced mortality from malaria in children <5 years of age.
• Dendritic cell-based vaccine against coccidioides infection.
• Doxorubicin transport by RALBP1 and ABCG2 in lung and breast cancer.
• Energy dependent transport of xenobiotics and its relevance to multidrug resistance.
• Evolution of schizophrenia drugs: A focus on dopaminergic systems.
• Hsf-1 and POB1 Induce Drug Sensitivity and Apoptosis by Inhibiting Ralbp1.
• Linking stress-signaling, glutathione metabolism, signaling pathways and xenobiotic transporters.
• Next generation of human vaccines: what does the future hold?
• RALBP1/RLIP76 mediates multidrug resistance.
• RLIP76 in Defense of Radiation Poisoning.
• Regression of lung and colon cancer xenografts by depleting or inhibiting RLIP76 (Ral-binding protein 1).
• Role of 4-hydroxynonenal and its metabolites in signaling.
• Self-regulatory role of 4-hydroxynonenal in signaling for stress-induced programmed cell death.
• Therapeutic resistance in lung cancer.